HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $11 to $15.
Stifel Initiates Coverage On OptimizeRx with Buy Rating, Announces Price Target of $19
Stifel analyst David Grossman initiates coverage on OptimizeRx (NASDAQ:OPRX) with a Buy rating and announces Price Target of $19.